This company listing is no longer active
Initiator Pharma Toekomstige groei
Future criteriumcontroles 5/6
Belangrijke informatie
21.5%
Groei van de winst
25.7%
Groei van de winst per aandeel
| Biotechs winstgroei | 45.6% |
| Inkomstengroei | 62.7% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | n/a |
Recente toekomstige groei-updates
Geen updates
Recent updates
Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2024 | 33 | -37 | -39 | -39 | 1 |
| 12/31/2023 | 106 | 44 | 51 | 51 | 1 |
| 12/31/2022 | N/A | -46 | -36 | -36 | 1 |
| 3/31/2022 | N/A | -34 | -40 | -40 | N/A |
| 12/31/2021 | N/A | -21 | -34 | -34 | N/A |
| 9/30/2021 | N/A | -16 | -29 | -29 | N/A |
| 6/30/2021 | N/A | -10 | -11 | -11 | N/A |
| 3/31/2021 | N/A | -8 | -10 | -10 | N/A |
| 12/31/2020 | N/A | -9 | -8 | -8 | N/A |
| 9/30/2020 | N/A | -10 | -8 | -8 | N/A |
| 6/30/2020 | N/A | -9 | -7 | -7 | N/A |
| 3/31/2020 | N/A | -9 | -8 | -8 | N/A |
| 12/31/2019 | N/A | -8 | -9 | -9 | N/A |
| 9/30/2019 | N/A | -7 | -7 | -7 | N/A |
| 6/30/2019 | N/A | -9 | -7 | -7 | N/A |
| 3/31/2019 | N/A | -8 | -10 | -10 | N/A |
| 12/31/2018 | N/A | -10 | -14 | -14 | N/A |
| 9/30/2018 | N/A | -13 | -16 | -16 | N/A |
| 6/30/2018 | N/A | -11 | -14 | -14 | N/A |
| 3/31/2018 | N/A | -10 | -11 | -11 | N/A |
| 12/31/2017 | N/A | -9 | -8 | -8 | N/A |
| 9/30/2017 | N/A | -7 | -4 | -4 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: INIT BTA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).
Winst versus markt: INIT BTA is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hoge groeiwinsten: INIT BTA is expected to become profitable in the next 3 years.
Omzet versus markt: INIT BTA's revenue (62.7% per year) is forecast to grow faster than the Swedish market (9.4% per year).
Hoge groei-inkomsten: INIT BTA's revenue (62.7% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if INIT BTA's Return on Equity is forecast to be high in 3 years time